Related Experiment Video
Updated: Jun 19, 2026
12:45
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Future of cardiac resynchronization therapy
Aruna Vishnu Arujuna1, Matthew Ginks, Aldo Rinaldi
1St Thomas' Hospital, SE1 7EH London, UK. arunavishnu@hotmail.com
Future Cardiology
|October 7, 2009
Summary
Cardiac resynchronization therapy (CRT) improves outcomes for heart failure patients with dyssynchrony. Research is exploring ways to help the 20-30% who don't benefit, showing promising results.
Area of Science:
- Cardiology
- Medical Devices
- Heart Failure Management
Background:
- Severe heart failure with electromechanical dyssynchrony often requires advanced treatment.
- Cardiac resynchronization therapy (CRT) is a recognized therapy for select patients.
- CRT combined with an internal cardiac defibrillator offers additional mortality benefits.
Purpose of the Study:
- To review evidence supporting current CRT patient selection guidelines.
- To identify challenges and limitations in current CRT practice.
- To explore emerging trends and future directions in CRT.
Main Methods:
- Review of pivotal clinical trials and guidelines for CRT.
- Analysis of patient response rates and non-responder cohorts.
- Discussion of ongoing research and future technological advancements in CRT.
Main Results:
- CRT is effective in a significant portion of heart failure patients with dyssynchrony.
- A notable percentage of patients (20-30%) do not respond to CRT.
- Emerging research indicates potential strategies to improve CRT efficacy.
Conclusions:
- CRT is a valuable therapy, but patient selection remains critical.
- Addressing non-responders is a key area for future CRT research.
- Advancements in patient selection and therapy optimization hold promise for broader CRT benefits.
More Related Videos
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:23Cardiopulmonary Resuscitation III: AED Use
Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...